It is the uneven winning trio of the Ibex so far this year. A bank –Sabadell (+49%) -, a company dedicated to the swimming pool and wellness sector -Fluidra (+ 38%)-, Y a biotech -PharmaMar (+ 34%)– are investors' favorites … and they have reason to do so. They have all announced good news of late. On this occasion, and although it is not always the case, there are news that justify their good behavior and that reaffirm them at the top of the selective.
During this week, both Sabadell and PharmaMar have made separate announcements that have clearly contributed to boost them on the stock market. The entity communicated this Friday a net profit of 73 million in the first quarter that, although it implies a drop of 22% compared to the same period a year ago, was above consensus. Analysts especially liked the numbers for their business activity, and are now waiting for the good prospects to be confirmed in the meeting with the board on May 28.
After going through difficult situations in the middle of the restructuring of the banking sector, with the announcement that the merger with BBVA would finally not go ahead, which immediately led to the Catalan bank being singled out as the most affected by this decision, it seems that the moment has now become more appropriate for the entity. The forecasts are also good, because the management team predicts an improvement in net interest income in 2021 and because the figures still do not reflect the synergies resulting from cost savings in Spain.
By technical analysis, Banco Sabadell pulverized on Friday, with the 8.7% rally after publishing its accounts, the annual maximums it had at 0.5020 euros. "The lateral movement of the last two months is ended and a change in trend is confirmed, so we could calmly see rises to the level of 0.6 euros, which would mean an almost 18% revaluation from current prices, "anticipates César Nuez, an analyst at Bolsamanía and head of Trader Watch.
FINALLY PHARMAMAR PHASE III
PharmaMar finally received the good news this week that the Spanish Agency for Medicines and Health Products (AEMPS) has authorized the passage to phase III of its trial for the use of Aplidin against Covid. Since the beginning of the year this 'ok' was expected, but in recent times some doubts had arisen about the possibility that it would not arrive. This announcement led on Thursday an 8% rally in the company, whose titles are once again approaching the level of 100 euros.
"Finally it has not been able to finish the week above the 97.50 euros that it exceeded on Thursday (it closed on Friday with falls of 3.75%, at 95 euros). If it manages to leave this level behind, could chain a recovery to the annual highs that it drew in February at 120 euros"anticipates Nuez.
AND FLUIDRA, WITH THE 30 EUROS 'AT THE STONE'
Since Fluidra celebrated its 'Capital Markets Day' and made very positive announcements about its forecasts for the coming years and about how well the sector is evolving, for which the pandemic has been a great shock, company stocks up 10%. Although it is expensive and most analysts are still very cautious about it, the truth is that others, like Berenberg, see it at 30 euros and clearly recommend 'buy'. There are reasons for it to continue rising, but the fact that it has appreciated no less than 280% in one year weighs heavily.
"It does not stop drawing new historical highs since August 2020, with a revaluation without any major correction. It continues very well and does not show any signs of weakness, but entering now involves a lot of risk", concludes César Nuez.
. (tagsToTranslate) Sabadell (t) Fluidra (t) PharmaMar: (t) string (t) good (t) news (t) for (t) trio (t) winner (t) Ibex (t) Category: All (t) ) Category: Company News (t) Category: Europe Report (t) Category: International News (t) Category: Pulses (t) Category: Pulses Europe (t) Category: Sectorial: Consumer Durables (t) Category: Sectorial: Finance ( t) mostread_ultimas (t) mostread_fundsnews (t) mostread_empresas (t) mostread_internacional